NEW YORK (Reuters) - Martin Shkreli, known for once hiking the price of a life-saving drug more than 4,000%, cannot return to the pharmaceutical industry after a federal appeals court on Tuesday upheld his lifetime ban.
A three-judge panel of the 2nd U.S. Circuit Court of Appeals in Manhattan said a lower court judge acted properly in imposing the ban and ordering Shkreli to repay $64.6 million because of his antitrust violations.
The case had been brought by the U.S. Federal Trade Commission (FTC), joined by New York, California, Illinois, North Carolina, Ohio, Pennsylvania and Virginia.
Shkreli, 40, became notorious and gained the sobriquet “Pharma Bro” when, as chief executive of Turing Pharmaceuticals in 2015, he raised the price of the newly-acquired antiparasitic drug Daraprim overnight to $750 per tablet from $17.50.
Lead to death of people by making their drugs unaffordable: now Martin, you’re not to work in the industry again
Sell drugs people literally begged you for and lead to death because you made their self treatment affordable: life in prison.
Who is the second one referring to?
Someone who sells someone heroin they overdose on.
What kind of functioning moral system could possibly make such a distinction?
You have led to a death either way. Why is one life worth less? The only logical conclusion is classism.